NOVAVAX INC (NVAX) Stock Price & Overview
NASDAQ:NVAX • US6700024010
Current stock price
The current stock price of NVAX is 8.12 USD. Today NVAX is down by -4.92%. In the past month the price decreased by -21.16%. In the past year, price increased by 38.57%.
NVAX Key Statistics
- Market Cap
- 1.323B
- P/E
- 3.37
- Fwd P/E
- N/A
- EPS (TTM)
- 2.41
- Dividend Yield
- N/A
NVAX Stock Performance
NVAX Stock Chart
NVAX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NVAX. When comparing the yearly performance of all stocks, NVAX is one of the better performing stocks in the market, outperforming 78.72% of all stocks.
NVAX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NVAX. There are concerns on the financial health of NVAX while its profitability can be described as average.
NVAX Earnings
On January 12, 2026 NVAX reported an EPS of 0.11 and a revenue of 147.14M. The company beat EPS expectations (122.14% surprise) and beat revenue expectations (59.82% surprise).
NVAX Forecast & Estimates
15 analysts have analysed NVAX and the average price target is 13.39 USD. This implies a price increase of 64.87% is expected in the next year compared to the current price of 8.12.
For the next year, analysts expect an EPS growth of -115.02% and a revenue growth -62.72% for NVAX
NVAX Groups
Sector & Classification
NVAX Financial Highlights
Over the last trailing twelve months NVAX reported a non-GAAP Earnings per Share(EPS) of 2.41. The EPS increased by 246.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 39.19% | ||
| ROA | 37.42% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NVAX Ownership
NVAX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.01 | 375.559B | ||
| AMGN | AMGEN INC | 15.38 | 191.693B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 176.393B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.5 | 113.496B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.02 | 81.177B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.17 | 42.608B | ||
| INSM | INSMED INC | N/A | 34.4B | ||
| NTRA | NATERA INC | N/A | 28.771B | ||
| BIIB | BIOGEN INC | 10.76 | 25.993B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.14 | 25.192B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| INCY | INCYTE CORP | 12.54 | 19.296B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.068B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVAX
Company Profile
The company is headquartered in Gaithersburg, Maryland and currently employs 749 full-time employees.
Company Info
IPO: 1973-05-16
NOVAVAX INC
21 Firstfield Rd
Gaithersburg MARYLAND 20878 US
CEO: Stanley C. Erck
Employees: 952
Phone: 18009279800
NOVAVAX INC / NVAX FAQ
Can you describe the business of NOVAVAX INC?
The company is headquartered in Gaithersburg, Maryland and currently employs 749 full-time employees.
What is the current price of NVAX stock?
The current stock price of NVAX is 8.12 USD. The price decreased by -4.92% in the last trading session.
What is the dividend status of NOVAVAX INC?
NVAX does not pay a dividend.
How is the ChartMill rating for NOVAVAX INC?
NVAX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does NOVAVAX INC belong to?
NOVAVAX INC (NVAX) operates in the Health Care sector and the Biotechnology industry.
Should I buy NVAX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NVAX.
Is NOVAVAX INC (NVAX) expected to grow?
The Revenue of NOVAVAX INC (NVAX) is expected to decline by -62.72% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.